Business News
The FDA approves Gamifant ® (EMAPALUMAB-LZSG) as the first treatment for adults and children with macrophage activation syndrome in Still’s disease

The FDA approves Gamifant ® (EMAPALUMAB-LZSG) as the first treatment for adults and children with macrophage activation syndrome in Still’s disease



